Stock ALVIO VALERIO THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Valerio Therapeutics

Equities

ALVIO

FR0010095596

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 16:35:25 26/04/2024 BST 		5-day change 1st Jan Change
0.11 EUR -2.65% Intraday chart for Valerio Therapeutics -6.78% -33.33%
2023 Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 Onxeo SA has Changed its Name to Valerio Therapeutics CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 54.72 44.31 32.42 52.01 38.52 15.64
Enterprise Value (EV) 1 40.57 40.1 35.29 43.74 30.57 11.19
P/E ratio -0.92 x -4.84 x -1 x 66.7 x -6 x -0.76 x
Yield - - - - - -
Capitalization / Revenue 5.76 x 7.23 x 7.56 x 29.3 x 9.48 x 10.8 x
EV / Revenue 4.27 x 6.54 x 8.23 x 24.6 x 7.53 x 7.75 x
EV / EBITDA -2.14 x -11.8 x -3.69 x -5.69 x -5.52 x -0.66 x
EV / FCF -3.4 x -7.11 x -8.03 x -4.87 x -4.16 x -3.83 x
FCF Yield -29.4% -14.1% -12.5% -20.5% -24.1% -26.1%
Price to Book 1.1 x 1.02 x 1.97 x 1.79 x 1.17 x 0.7 x
Nbr of stocks (in thousands) 50,666 50,815 58,407 77,977 91,722 111,059
Reference price 2 1.080 0.8720 0.5550 0.6670 0.4200 0.1408
Announcement Date 25/04/18 09/04/19 27/04/20 23/04/21 28/04/22 29/04/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 9.505 6.127 4.289 1.776 4.062 1.443
EBITDA 1 -18.99 -3.385 -9.564 -7.69 -5.535 -17.04
EBIT 1 -19.19 -3.527 -9.795 -7.814 -5.582 -17.11
Operating Margin -201.88% -57.56% -228.37% -439.98% -137.42% -1,185.93%
Earnings before Tax (EBT) 1 -66.87 -11.16 -36.05 1.846 -5.837 -19.28
Net income 1 -59.07 -9.399 -33.73 1.089 -5.937 -19.56
Net margin -621.47% -153.4% -786.38% 61.32% -146.16% -1,355.65%
EPS 2 -1.170 -0.1800 -0.5531 0.0100 -0.0700 -0.1850
Free Cash Flow 1 -11.95 -5.636 -4.395 -8.974 -7.357 -2.919
FCF margin -125.68% -91.99% -102.47% -505.3% -181.11% -202.27%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 25/04/18 09/04/19 27/04/20 23/04/21 28/04/22 29/04/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 2.87 - - -
Net Cash position 1 14.1 4.21 - 8.27 7.95 4.45
Leverage (Debt/EBITDA) - - -0.3005 x - - -
Free Cash Flow 1 -11.9 -5.64 -4.4 -8.97 -7.36 -2.92
ROE (net income / shareholders' equity) -82.1% -19.7% -108% 4.71% -19.2% -70.9%
ROA (Net income/ Total Assets) -11.8% -3.12% -12.1% -11.6% -7.01% -22.2%
Assets 1 500.4 301.3 277.9 -9.38 84.72 87.93
Book Value Per Share 2 0.9900 0.8500 0.2800 0.3700 0.3600 0.2000
Cash Flow per Share 2 0.2800 0.2100 0.0900 0.1900 0.2000 0.1300
Capex 1 0.07 0.05 0.03 0.12 0.14 0.49
Capex / Sales 0.68% 0.73% 0.61% 6.7% 3.42% 33.82%
Announcement Date 25/04/18 09/04/19 27/04/20 23/04/21 28/04/22 29/04/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.11 EUR
Average target price
1.2 EUR
Spread / Average Target
+990.91%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VALERIO THERAPEUTICS Stock Valerio Therapeutics
-33.33% 18.09M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ALVIO Stock
  4. Financials Valerio Therapeutics